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Summary
Improvement of survival in lymphocytic leukaemia has been accompanied
by the occurrence of second primary cancer (SPCs). Based on Swedish
Family Cancer Database, we applied bi-directional analyses in which rela-
tive risks (RRs) were calculated for any SPCs in patients with chronic lym-
phocytic leukaemia (CLL), acute lymphoblastic leukaemia (ALL) and hairy
cell leukaemia (HCL) and the risks of these leukaemias as SPCs. After CLL,
RRs were significant for 20 SPCs, and high for skin squamous cell cancer
(2458 for in situ and 763 for invasive), Merkel cell carcinoma (1436),
Hodgkin lymphoma (716) and Kaposi sarcoma (676). Conversely, 15 CLL
cancer pairs were reciprocally increased. The increased risks were reciprocal
for ALL and four cancers. RR for ALL was 1535 after myeloid neoplasia.
HCL showed reciprocally increased RRs with non-Hodgkin lymphoma and
melanoma. The concordance between RRs for bi-directional associations
between CLL and different cancers, and HCL and different cancers was
highly significant. For CLL (also for HCL), the bi-directional risks with
skin cancers and other immune-related cancers suggest the probable
involvement of immune dysfunction. For ALL, treatment may contribute
to risks of multiple SPCs. Increased risk of ALL after haematological neo-
plasms may indicate bone marrow dysfunction. These findings may help
guide treatment decisions and prognostic assessment.
Keywords: B cell leukaemia, second cancers, immune suppression,
bi-directional risk, mechanistic implication.
Chronic lymphocytic leukaemia (CLL), which is the most
common type of leukaemia, is characterized by a progressive
clonal accumulation of phenotypically mature malignant B
lymphocytes in the blood, bone marrow and lymph nodes
(Nabhan & Rosen, 2014; Kipps et al, 2017). Established risk
factors for CLL include monoclonal B-cell lymphocytosis,
family history, mutations in shelterin complex genes, over 40
low-risk gene variants and exposure to some pesticides
(Speedy et al, 2014, 2016; Kipps et al, 2017; Law et al, 2017;
Leonard et al, 2017). Autoimmune conditions, such as
autoimmune haemolytic anaemia and immune thrombocy-
topenic purpura, are both risk factors and therapy-related
comorbidities (Hemminki et al, 2013; Kipps et al, 2017).
CLL can be divided into two main subtypes, according to
whether CLL cells express an unmutated or mutated
immunoglobulin heavy-chain variable region gene (Kipps
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et al, 2017). Numerous genetic changes take place during the
evolution of CLL, including somatic mutations and chromo-
somal aberrations (Kipps et al, 2017; Burns et al, 2018).
Many patients are diagnosed at an asymptomatic stage with
monoclonal B-cell lymphocytosis and may not initially
require treatment, but once entering the symptomatic stage
management strategies include chemotherapy with alkylating
agents and purine analogues, combination of chemotherapy
and immunotherapy, and recently, drugs that target key sig-
nalling pathways (Kristinsson et al, 2009; Nabhan & Rosen,
2014; Kipps et al, 2017). Many second primary cancers
(SPCs) have been found to be increased in patients with
CLL, including non-melanoma skin cancer, melanoma, sar-
coma and lung, renal and prostate cancers (Morton et al,
2010; Royle et al, 2011; Beiggi et al, 2013). Approximately
2% and 5% of CLL transforms to an aggressive non-Hodgkin
lymphoma (NHL) or Hodgkin lymphoma (HL) (Richter syn-
drome) (Kipps et al, 2017). Small lymphocytic lymphoma
can be diagnosed in 5% of patients with CLL (Nabhan &
Rosen, 2014; Kipps et al, 2017).
Adult (diagnosed at 20 years or older) acute lymphoblastic
leukaemia (ALL) constitutes about 40% of ALL cases, 75% of
which are B-cell lineage and 25% are T-cell lineage (Al Ustwani
et al, 2016). Recurrent cytogenetic abnormalities are found in
70% of adults and 90% of children with ALL while the
Philadelphia chromosome (BCR-ABL1 fusion) is far more
common in adults (15–30%) than in children (2%) (Inaba
et al, 2013; Al Ustwani et al, 2016; Jabbour et al, 2018). Other
fusion genes are common in adult as well as childhood ALL
(Inaba et al, 2013; Jabbour et al, 2018). Cytotoxic therapies,
which are effective in childhood ALL, have generally been inef-
fective for management of adult ALL, where long term survival
remains generally poor (Rowe, 2010). Risk factors for SPC
after ALL are largely unknown and data on SPCs are limited,
although one trial observed an increased risk for lymphoprolif-
erative neoplasms (Tavernier et al, 2007).
Hairy cell leukaemia (HCL) is a rare B-cell disease typified
by somatic BRAF mutations (Grever et al, 2014; Leonard
et al, 2017). Clinical features at presentation generally include
splenomegaly, lymphocytosis and monocytopenia with an
underlying immunocompromised state (Getta et al, 2015).
Infectious complications have been a hallmark of the clinical
course in HCL patients but to what extent the immunocom-
promised state is the result of the underlying disease or fol-
lowing immunosuppressive chemotherapy remains unclear
(Grever et al, 2014). Many patients have an indolent course
and no therapies are initially required (Dinmohamed et al,
2018). Therapies based on purine analogues were developed
in 1990, which achieve good response rates, and, more
recently, targeted treatments have become available, including
inhibition of the mutated BRAF kinase (Grever et al, 2014;
Getta et al, 2015). Since 1990, relative survival has been simi-
lar to that of the background population among patients
diagnosed before the age of 60 years, and has now improved
to some 90%, even among elderly people (Dinmohamed
et al, 2018). An increased risk of SPCs in HCL patients has
been reported for HL, NHL and thyroid cancer, for which
HCL-related immunological impairment was suggested to
contribute (Hisada et al, 2007; Cornet et al, 2014; Dasanu
et al, 2015).
In this study, we analysed individual data from the Swed-
ish Cancer Registry to assess the risks of SPCs following
diagnosis of CLL, ALL and HCL, and also the risk of these
leukaemias after the diagnosis of another cancer. Even
though many studies have published the risks of SPC after
CLL and some have been published after HCL, no previous
studies have analysed the risks of leukaemias as SPC. The bi-
directional analysis was recently applied for myeloid
neoplasms and NHL in providing evidence for reciprocal
relationships between cancer risks (Chattopadhyay et al,
2018a,b). The findings from bi-directional analyses may give
insight concerning the mechanisms of SPC, particularly on
the contribution of the adverse consequence of therapy, as
therapies are rarely identical for two cancers. These findings
may provide evidence that an immune-suppressed state may
be the key mechanism if bi-directional risks are found.
Patients and methods
The Swedish Family Cancer Database includes the Swedish
population organized in family data and is linked to the
Swedish Cancer Registry, which was founded in 1958; it cov-
ers the entire population and includes more than two million
cancers registered since 1958 (Hemminki et al, 2010). Six
regional registries were created in the mid-1980s, which are
associated with the oncological centres in each medical
region of Sweden, and where the registration, coding and
major check-up and correction work is performed. The
regionalization implies a high-quality service through close
contact between the Swedish Cancer Registry at the regional
level and the reporting clinician, thus simplifying the under-
taking of correcting and checking the data.
The registry is based on compulsory cancer notifications from
clinicians and pathologists/cytologists (Pukkala et al, 2017).
Adult (>20 years) CLL, ALL and HCL patients were iden-
tified from the database. Over 95% of all registered lympho-
cytic leukaemia cases were histologically verified. While the
cancer registry does not publish specific statistics on histolog-
ical verification of SPCs, these are included with primary
cancers, for which histological verification has been approxi-
mately 98% since the 1970s (Centre for Epidemiology, 2013).
An ad hoc study on the diagnostic accuracy of second neo-
plasms found that 98% were correctly classified (Fr€odin et al,
1997). Cancer types were identified through revisions 7 and
10 of the International Classification of Diseases (ICD) in
combination with SNOMED (ICD-O2) codes that were
introduced in 1993. Subtypes of invasive skin cancers,
including squamous cell carcinoma (SCC), Merkel cell cancer
and Kaposi sarcoma, as well as in situ skin cancer were
included. Myeloid malignancies included acute (AML) and
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chronic myeloid leukaemia (CML), myelodysplastic syndromes
(MDS) and myeloproliferative neoplasms (MPN). The follow-
up was started from the year of diagnosis and terminated at
death, detection of a SPC, emigration or 31 December 2015,
whichever came first.
A Poisson regression model was used to estimate relative
risks (RRs) for SPCs by comparing incidence rates for each
SPC in patients with lymphocytic leukaemia to the respective
incidence of this cancer as first primary cancer in the refer-
ence population aged 20 years or older. In the reverse analy-
sis, RRs for lymphocytic leukaemia were considered as SPCs
following any primary cancer in patients aged 20 years or
older. The patients with CLL, ALL and HCL diagnosed
between 1971–1985, 1986–2000 and 2001–2015 (HCL data
were available only for the last two periods) were followed
for 15 years from the time of diagnosis to estimate the peri-
odic risks for a SPC. Sex, age group (5-year bands), calendar
period (5-year bands), residential area (large cities, South
Sweden, North Sweden or unspecified) and socioeconomic
status (blue-collar worker, white-collar worker, farmer, pri-
vate, professional or other/unspecified) were adjusted in the
regression model. Confidence intervals (CIs) were calculated
for 5%, 1% and 01% level of significance. The concordance
between RRs of cancer sites that were both significant in the
bi-directional analyses was assessed by Spearman rank-order
correlation. All analyses were performed in SAS (v9.4) (SAS
Institute, Cary, NC, USA).
The study was approved by the Ethical Committee of
Lund University without a requirement for informed con-
sent. Through advertisements in major newspapers people
could choose to opt out of the study before the research reg-
ister was constructed. The project database is located at Cen-
tre for Primary Health Care in Malm€o, Sweden. The study
was conducted in accordance with the approved guidelines.
Results
Basic demographic data on the study population are pro-
vided in Table I. CLL was by far the largest diagnostic cate-
gory, with 18,407 patients diagnosed at a median age of
71 years; 2773 SPCs (151%) were diagnosed with a median
follow-up time of 4 years. For ALL, the patient number was
2474 and for HCL it was 823, followed by 168 (70%) and
150 (182%) SPCs, respectively. The respective median diag-
nostic ages were 63 and 62 years. CLL was diagnosed as a
SPC in 2010 cancer patients, ALL in 179 patients and HCL
in 97 patients.
Risks for SPCs following diagnosis of CLL and risks of
CLL following diagnosis of non-CLL cancers are shown in
Table II. Only cancer sites with at least 10 cases or significant
results are shown, which is same for the following tables.
Overall, the risk of SPC was increased to 196. RRs were sig-
nificant for 20 cancers with the largest RRs being shown after
skin squamous cell cancer (2458 in situ and 763 invasive),
Merkel cell carcinoma (1436), HL (716) and Kaposi
sarcoma (676). In the reverse analysis, for CLL as a SPC, the
overall risk was significantly increased to 130 (Table II, right
set of columns). RRs were significantly increased for second
CLL after 16 cancers with the largest RRs being shown after
Merkel cell carcinoma (739), Kaposi sarcoma (526), inva-
sive skin cancer (302), NHL (296) and myeloid neoplasia
(232). A total of 15 CLL cancer pairs were reciprocally
increased. The concordance between the RR for each non-
CLL cancer following a diagnosis of CLL and the RR for
CLL following diagnosis of a non-CLL cancer was highly sta-
tistically significant (r = 067, P = 0006).
Table III shows the RRs for SPC after ALL and for ALL as
a SPC. The overall RR was increased to 213 for SPC after
ALL. The risks for 14 cancers were increased, with the high-
est RRs recorded for HL (1465), in situ skin cancer (781),
endocrine tumours (561), invasive skin cancer (520), kidney
cancer (502) and NHL (492). In the reverse analysis, the
overall RR was 151. Risks for ALL after six cancers were
increased, most after myeloid neoplasia (1535), HL (814)
and NHL (678); for six cancers the increased risks were
reciprocal. The primary myeloid neoplasias preceding ALL
included AML (n = 4), CML (n = 9), MDS (n = 2) and
MPN (n = 5); the median follow-up time from myeloid neo-
plasm to ALL was 25 months. The concordance between RR
for each non-ALL cancer following a diagnosis of ALL and
RR for ALL following diagnosis of a non-ALL cancer was not
significant (r = 060, P = 03). No cases of Merkel cell cancer
or Kaposi sarcoma were found in these analyses.
Table IV shows the RRs for SPC after HCL and for HCL
as a SPC. The overall RR was increased to 165 for SPC after
HCL, contributed by eight cancers with increased RRs. The
highest RR was found for nasal cancer, but this was based on
one case only; the RRs for NHL was 470, for in situ skin can-
cer it was 417 and for invasive skin cancer it was 362, barely
higher than the RR for kidney cancer (360). In the reverse
analysis, the overall RR was 162, with HCL risk increased
after three cancers, most after NHL (599). NHL and mela-
noma showed reciprocally increased RRs. The concordance
between RR for each non-HCL cancer following a diagnosis of
HCL and RR for HCL following diagnosis of a non-HCL can-
cer was highly statistically significant (r = 100).
Periodic analyses of SPC risks related to the three types of
leukaemia are reported in Tables SI–SVI. Each follow-up per-
iod was about 15 years, which allows comparison between
the periods. Risk of SPC after CLL is shown in Table SI, with
a stable overall risk of about 20. Skin SCC was increased
through all periods (RRs between 673 and 912) but the
high risk of HL was noted only in the last two periods. In
the reverse order (Table SII), i.e., CLL as a SPC, the overall
RRs were stable at around 14, and CLL was increased after
skin SCC through all periods (RRs between 305 and 455).
The results for ALL and HCL were inconclusive because of
small case numbers. However, the risk of ALL was extremely
high (RR over 40) as a SPC after myeloid malignancies in
the last two follow-up periods.
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Table I. Distribution of patients with leukaemia.
Leukaemia N Age at diagnosis (years); median (range) Follow-up time to SPC (years); median (range) SPC, n (%)*
Leukaemia as first primary cancer
CLL 18 407 71 (63–79) 4 (1–8) 2773 (151)
ALL 2474 63 (46–74) 3 (0–85) 168 (70)
HCL 823 62 (51–71) 8 (3–12) 150 (182)
Leukaemia as second primary cancer, after around 163 million first primary cancers*
CLL 2010 76 (70–82) 5 (1–12)
ALL 179 72 (63–78) 5 (2–11)
HCL 97 72 (66–79) 5 (2–10)
ALL, acute lymphoblastic leukaemia; CLL, chronic lymphocytic leukaemia; HCL, hairy cell leukaemia; SPC, second primary cancer.
*not including leukaemia.
Table II. Risk of cancer after diagnosis of CLL and that of CLL after diagnosis of cancer.
Cancer site
Risk of cancer after CLL Risk of CLL after cancer
N RR Lower Upper N RR Lower Upper
UAT 60 202 157 260 42 103 076 139
Oesophagus 12 090 051 159 7 156 074 326
Stomach 82 150 121 186 38 101 074 139
Small intestine 11 178 099 322 5 093 039 223
Colorectum 247 136 120 154 215 116 102 133
Liver 53 129 098 168 15 159 096 263
Pancreas 45 111 083 149 2 022 006 089
Nose 5 241 100 580 2 072 018 289
Lung 246 238 210 270 48 133 100 176
Breast 115 079 066 095 239 081 072 093
Cervix 9 126 066 242 21 056 036 086
Endometrium 32 114 081 161 70 083 066 105
Ovary 20 108 070 168 32 086 061 122
Prostate 403 120 109 133 465 157 143 173
Kidney 74 206 164 259 56 148 114 193
Bladder 134 184 155 218 126 147 124 176
Melanoma 127 322 271 383 97 147 120 18
SCC, invasive 639 763 706 825 183 302 261 350
Merkel 11 1436 790 2609 3 739 238 2292
Kaposi 5 676 280 1629 4 526 198 1402
Skin SCC, in situ 235 2458 2158 2800 231 260 228 296
Nervous System 66 254 200 324 47 124 093 165
Thyroid 11 158 088 286 31 185 130 263
Endocrine 25 157 106 232 53 132 101 173
Connective tissue 17 232 144 374 18 187 118 297
NHL 130 311 262 37 108 296 245 358
Hodgkin lymphoma 26 716 487 1053 11 199 110 359
Myeloma 26 126 086 185 13 091 053 156
Myeloid malignancies 53 212 162 278 36 232 168 322
UPC 91 188 153 231 6 041 019 092
All cancers* 2773 196 189 204 2010 130 124 136
Bold, italicized and underlined indicate statistical significance at 5%, 1% and 01% level respectively.
CLL, chronic lymphocytic leukaemia; N, frequency; NHL, non-Hodgkin lymphoma; RR, relative risk; SCC, squamous cell carcinoma; UAT, upper
aerodigestive tract; UPC, unknown primary cancer.
*Leukaemia has been excluded from “All cancers”.
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Discussion
The novel aspect of the present study was the bi-directional
analysis of SPCs, which will allow mechanistic insight into the
formation of SPCs. The risk of NHL was increased as a SPC
after CLL, ALL and HCL, and the risk for each leukaemia was
increased as a SPC after NHL. The correlations of the bi-direc-
tional associations were highly significant for CLL and HCL
but not for ALL. Invasive and in situ skin cancers, HL, mela-
noma and kidney cancer were most systematically associated
as first cancer and SPC with the three leukaemias. The pattern
of associated cancers provides strong epidemiological evidence
that immune dysfunction plays a role. Immunosuppressed
organ transplant patients have an increased risk of skin SCC
and NHL (20-fold) but also kidney cancer (15-fold), mela-
noma, leukaemia and anogenital cancers (5-fold) and other
Table III. Risk of cancer after diagnosis of ALL and that of ALL after diagnosis of cancer.
Cancer site
Risk of cancer after ALL Risk of ALL after cancer
N RR Lower Upper N RR Lower Upper
Colorectum 17 16 100 258 23 164 108 247
Lung 20 345 223 535 4 134 050 359
Breast 11 107 059 194 38 164 119 226
Prostate 21 157 102 24 28 143 098 209
Testis 0 – – – 3 375 121 1166
Kidney 12 502 285 884 3 099 032 306
Bladder 10 243 131 452 10 161 086 300
SCC, invasive 18 520 327 825 6 148 066 33
Skin SCC, in situ 3 781 252 2422 6 105 047 235
Nervous System 5 258 107 62 1 031 004 219
Endocrine 6 561 252 1249 4 135 051 361
Connective tissue 2 414 104 1656 1 126 018 895
NHL 11 492 272 888 18 678 426 108
Hodgkin lymphoma 5 1465 609 3521 5 814 338 1957
Myeloid malignancies 5 353 147 847 20 1535 987 2385
UPC 6 234 105 522 1 078 011 557
All* 168 213 183 248 179 151 129 176
Bold, italicized and underlined indicate statistical significance at 5%, 1% and 01% level respectively.
ALL, acute lymphoblastic leukaemia; N, frequency; NHL, non-Hodgkin lymphoma; RR, relative risk; SCC, squamous cell carcinoma; UPC,
unknown primary cancer.
*Leukaemia has been excluded from “All cancers”.
Table IV. Risk of cancer after diagnosis of HCL and that of HCL after diagnosis of cancer.
Cancer site
Risk of cancer after HCL Risk of HCL after cancer
N RR Lower Upper N RR Lower Upper
Colorectum 18 172 109 274 10 161 086 301
Nose 1 914 129 6492 0 – – –
Prostate 39 115 084 157 31 226 156 326
Kidney 7 360 172 755 3 210 068 653
Melanoma 9 259 134 497 9 253 131 489
SCC, invasive 18 362 228 575 3 15 048 466
Skin SCC, in situ 3 417 135 1295 6 188 084 42
NHL 13 470 273 810 10 599 321 112
UPC 6 234 105 521 0 – – –
All* 150 165 140 193 97 162 131 201
Bold, italicized and underlined indicate statistical significance at 5%, 1% and 01% level respectively.
HCL, hairy cell leukaemia; N, frequency; NHL, non-Hodgkin lymphoma; RR, relative risk; SCC, squamous cell carcinoma; UPC, unknown
primary cancer.
*Leukaemia has been excluded from “All cancers”.
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cancers (Birkeland et al, 1995; Wimmer et al, 2007; Rama &
Grinyo, 2010). The bidirectional spectrum of cancer risk seen
in the present analysis is reminiscent of immunosuppressed
patients. This is in contrast to the conclusions of a recent
review on CLL, which stated that ‘. . . malignancies observed
do not mirror those in patients with other immunodeficiency
diseases’ (Kipps et al, 2017). For CLL, very high reciprocal
risks of Merkel cell cancer were noted, as has been previously
reported as SPC after CLL (Tadmor et al, 2011, 2012). We also
found novel reciprocal associations of CLL with Kaposi sar-
coma, which was not significant in a previous study (Morton
et al, 2010). As both Kaposi sarcoma and Merkel cell carci-
noma are virally induced and associated with immunodefi-
ciency conditions, including autoimmune diseases, the strong
associations of these cancers with CLL provide further evi-
dence on underlying immunological mechanisms (Zur Hau-
sen, 2009; Hemminki et al, 2012).
The strengths of this study were the nationwide coverage of
cancers from a cancer registry where virtually all cancers have
been histologically verified. The obligation to report cancers
to the cancer registry has included SPCs, and international
pooling studies have shown that the Swedish rates of SPCs are
among the highest of all cancer registries (Brennan et al,
2005). In agreement, the present study found the proportion
of SPCs after CLL to be 151%, higher than 91% in the US
study based on the statistics in the Surveillance, Epidemiol-
ogy, and End Results (SEER) database (Morton et al, 2010).
Similarly, the present proportion of SPCs after HCL of 182%
was higher than that of 115% reported in the SEER database
(Hisada et al, 2007). The present proportion for ALL was
lowest (70%) among the three leukaemias, which most likely
indicates that these proportions are related to survival in the
particular cancers. Accordingly, the median follow-up times
decreased from HCL (8 years) to CLL (4 years) and ALL
(3 years). A limitation of the study was that we did not have
the opportunity to incorporate information on treatment.
Previous studies have not considered myeloid neoplasia as
SPC after CLL or other leukaemias. The present results showed
that myeloid neoplasia were bi-directionally associated with
CLL and ALL. The risk of ALL was very high (1535) as a SPC,
which was observed in the period 1986–2015. The related mye-
loid neoplasia included all main types of this disease and ALL
diagnosis followed after a median of only 25 months, suggest-
ing generalized bone marrow dysfunction as a possible mecha-
nism. However, this was not reflected in a general immune
dysfunction since ALL risk after skin cancer was not increased.
Risk of ALL was increased bi-directionally with NHL and HL.
The risks of many cancers were increased after ALL, to which
chemotherapy may have contributed. As an example, ALL risk
was increased after testicular cancer, for which the normal
treatment includes radiotherapy and a combination of DNA-
damaging drugs (Hanna & Einhorn, 2014). In a clinical trial of
adult ALL patients, 40% of 23 SPCs were myeloid neoplasia
and the remaining cases were equally divided between skin and
internal tumours and lymphoma (Tavernier et al, 2007).
Richter syndrome is estimated to account for 2–5% of
CLL patients whose disease transforms to NHL or HL, thus
some of the observed risks may be contributed by this mech-
anism (Kipps et al, 2017). However, this mechanism is unli-
kely to operate in the reverse order and the risk of CLL was
almost equally high (296) as a SPC after NHL as was the
risk of NHL after CLL (311).
Factors influencing malignant transformation of CLL
include genetic alterations, aberrant immune signalling and
growth stimulation by the cellular environment (Kipps et al,
2017). Immune signalling is thought to be triggered by sur-
face immunoglobulin acting as an autoantigen and leading to
a constitutively active B-cell receptor (Kipps et al, 2017). The
steps leading to clinical hypogammaglobulinaemia remain
unclear, but may involve systemic increases of interleukin 10
levels with ensuing immunosuppression. CLL cells express
high levels of the programmed cell death ligands PD-L1 and
PD-L2 (also termed CD274 and PDCD1LG2), which sup-
press T-cell effector functions leading to clonal expansion of
malignant cells (Kipps et al, 2017). Tumours can interfere
with T-cell orchestrated immune function, which mirrors the
impact of iatrogenic immune suppression, resulting in the
immunological escape of dormant tumours (which were in
immunological equilibrium) and, finally, a diagnosis of an
SPC (Friman et al, 2016).
In conclusion, we have provided a comprehensive bi-direc-
tional analysis of cancer risks associated with CLL, ALL and
HCL. For CLL, the bi-directional risks with NHL, skin SCC,
Merkel cell carcinoma and Kaposi sarcoma suggest that not
only immune dysfunction in CLL predisposes to multiple SPCs
but cancer-related immune dysfunction is able to trigger for-
mation of CLL as a SPC. For ALL, treatment may be an impor-
tant contributor to the risks of multiple SPCs. ALL risk was
increased as a SPC after myeloid neoplasms and lymphoma,
which may indicate bone marrow dysfunction. For the rare
HCL, the results were in-line with known immune dysfunc-
tion. As a clinical take-home message, the study quantified
risks for SPC, guiding treatment decisions and prognostic
assessment. Benefit-risk ratios of therapies need to be con-
stantly evaluated, which may suggest less cytotoxic treatment
options or reduction of treatment intensity in certain individu-
als, as in HL. Research needs to be intensified on the manage-
ment of patients on targeted agents, including inhibitors of
BRAF, BCL2, BTK and PI3K, many of which influence the
function of the immune system. In a broader context, target
and off-target effects of immunotherapy reagents, such as anti-
PD1, anti-PDL1 and anti-CTLA4, are a continued challenge.
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